Barclays Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $14.00

Travere Therapeutics (NASDAQ:TVTX) had its price objective increased by Barclays from $12.00 to $14.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an overweight rating on the stock.

Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a buy rating and issued a $19.00 target price on shares of Travere Therapeutics in a report on Tuesday, May 7th. Canaccord Genuity Group raised their price objective on shares of Travere Therapeutics from $15.00 to $18.00 and gave the stock a buy rating in a report on Tuesday, May 7th. Finally, Wedbush boosted their target price on Travere Therapeutics from $13.00 to $16.00 and gave the stock an outperform rating in a report on Friday. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Travere Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $15.27.

Travere Therapeutics Trading Down 5.2 %

NASDAQ TVTX opened at $8.53 on Friday. The company has a debt-to-equity ratio of 5.10, a current ratio of 2.78 and a quick ratio of 2.75. Travere Therapeutics has a twelve month low of $5.12 and a twelve month high of $15.90. The company’s 50-day simple moving average is $8.40 and its 200 day simple moving average is $7.74.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Monday, May 6th. The company reported ($1.76) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.78). The company had revenue of $41.40 million for the quarter, compared to the consensus estimate of $43.46 million. Travere Therapeutics had a negative return on equity of 207.40% and a negative net margin of 82.14%. Travere Therapeutics’s quarterly revenue was up 34.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.27) EPS. As a group, analysts predict that Travere Therapeutics will post -3.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC boosted its stake in Travere Therapeutics by 9.2% in the first quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock valued at $142,000 after acquiring an additional 1,557 shares during the last quarter. Arizona State Retirement System raised its position in shares of Travere Therapeutics by 9.7% during the 4th quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock valued at $189,000 after acquiring an additional 1,851 shares during the last quarter. Signaturefd LLC raised its position in shares of Travere Therapeutics by 1,656.4% during the 4th quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after acquiring an additional 2,849 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Travere Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock valued at $240,000 after acquiring an additional 2,948 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Travere Therapeutics by 7.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock valued at $417,000 after acquiring an additional 3,083 shares during the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.